by Rebecca F Baggaley, Michael A Irvine, Werner Leber et al.
The Lancet HIV 2017; 4: e465–74 – Published Online July 30, 2017
Early HIV diagnosis reduces morbidity, mortality, the probability of onward transmission, and their associated costs, but might increase cost because of earlier initiation of antiretroviral treatment (ART). The authors investigated this trade-off by estimating the cost-effectiveness of HIV screening in primary care. They conclude that screening for HIV in primary care has important public health benefits as well as clinical benefits. However, this intervention might be cost-effective far sooner, and even cost-saving, in settings where long-term health-care costs of late-diagnosed patients in high-prevalence regions are much higher (≥60%) than those of patients diagnosed earlier. Screening for HIV in primary care is cost-effective and should be promoted.